Arch Bronconeumol. 2017;53(2):43–44

Sociedad Española de Neumología y Cirugía Torácica SEPAR

ARCHIVOS DE Bronconeumología

www.archbronconeumol.org



Editorial

Skeletal Muscle Dysfunction in COPD: Novelties in the Last Decade☆

Disfunción de la musculatura esquelética en la EPOC: novedades de la última década

Esther Barreiro[a,b,c]

[a] Servicio de Neumología-Debilidad muscular y caquexia en las enfermedades respiratorias crónicas y el cáncer de pulmón, IMIM-Hospital del Mar, Barcelona, Spain
[b] Departament de Ciències Experimentals i de la Salut (CEXS), Universitat Pompeu Fabra (UPF), Parc de Recerca Biomédica de Barcelona (PRBB), Barcelona, Spain
[c] Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain

Skeletal muscle dysfunction, characterized by impairment in the strength and/or endurance properties of muscles, is a relevant systemic manifestation in patients with chronic cardiac and respiratory conditions such as chronic obstructive pulmonary disease (COPD). Muscle dysfunction negatively affects exercise capacity in these patients, thus diminishing their quality of life. Furthermore, muscle dysfunction and wasting of the lower limbs has been shown to predict disease morbidity and mortality regardless of the airway obstruction.[1–3] Several factors and biological mechanisms are involved in the multifactorial etiology of muscle dysfunction in COPD.[4] Interestingly, while both respiratory and peripheral muscles are disturbed in these patients, the latter are usually more severely affected, and have been the subject of abundant research in the last two decades. Evidence has also shown that several cellular and molecular events are differentially expressed in the respiratory and limb muscles of patients with COPD. This editorial aims to provide an overview of the most relevant biological mechanisms that have so far been shown to participate in the pathophysiology of lower limb muscle dysfunction in patients with COPD.

In the last two decades, several advances have been made in the identification of the biological mechanisms underlying muscle dysfunction in COPD. An understanding of the most relevant contributing mechanisms in this condition will help clinicians design therapeutic strategies that will alleviate muscle mass loss and dysfunction in patients with COPD. An increase in oxidative stress, as measured by protein oxidation levels, has been demonstrated repeatedly in the limb muscles of patients with COPD.[4] Moreover, oxidative stress markers were also shown to inversely correlate with clinical parameters, such as exercise capacity, body composition, and quadriceps strength inpatients with COPD.[5] These results suggest that oxidative events may hamper muscle function by altering key cellular processes involved in muscle contraction. Indeed, the content of several specific muscle proteins such as creatine kinase and myosin heavy chain was reduced in the vastus lateralis of patients with severe COPD and muscle wasting, while increased levels of oxidation was detected in the same proteins.[5–7] Systemic levels of oxidative stress have also been demonstrated in patients with COPD.[7,8]

Several markers of the ubiquitin-proteasome system were consistently upregulated in the lower limb muscles of COPD patients.[4,6,7] Moreover, the number of autophagosomes and the expression of other autophagy markers were also increased in the vastus lateralis of patients with severe COPD and muscle mass loss.[4,7,9] Importantly, several redox signaling cellular pathways such as nuclear factor (NF)-κB, forkhead box (FoxO)1 and FoxO3 are likely to mediate the loss of muscle mass in patients with severe COPD and cachexia.[6,7] Increased levels of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling-positive nuclei were also seen in the vastus lateralis of severe COPD patients with normal body composition, whereas muscle levels of ultrastructural apoptosis were low and did not differ from those detected in healthy controls.[4,10]

Epigenetic control of cells, defined as the process whereby gene expression is regulated by heritable mechanisms that do not affect DNA sequence, has recently emerged as a potential biological mechanism that may regulate muscle function and mass in COPD. The epigenetic modifications identified so far in cells are the following: (1) DNA methylation, (2) histone acetylation, (3) histone methylation, and (4) non-coding RNAs such as microRNAs. The epigenetic events modify gene transcription in different ways, for example, DNA methylation at the 5 position of cytosine specifically reduces gene expression. Acetylation is a transient, enzymatically controlled biochemical process, and is the most common posttranslational modification of histones. Acetylation, a process mediated by histone acetyltransferases (HTA), results in a rather open chromatin structure that is transcriptionally active, while deacetylation, through the action of histone deacetylases (HDAC), blocks transcription. Additionally, methylation of histones may activate or repress gene transcription, depending on the proteins recruited to the chromatin.

Evaluation of the expression of microRNAs has recently attracted much attention in the study of the etiology of respiratory

☆ Please cite this article as: Barreiro E. Disfunción de la musculatura esquelética en la EPOC: novedades de la última década. Arch Bronconeumol. 2017;53:43–44.

E-mail address: ebarreiro@imim.es

diseases. MicroRNAs, encoded by eukaryotic nuclear DNA, are non-coding single-stranded RNA molecules (18–24 nucleotides) that function in the post-transcriptional regulation of gene expression. Interestingly, they exert their action via base-pairing with complementary sequences in mRNA molecules that result in gene silencing via translational repression or target degradation. MicroRNAs may have different mRNA targets, and a given mRNA may also be targeted by multiple microRNAs. MicroRNAs regulate many physiological cellular processes, and may play a significant role in the pathogenesis of several lung diseases including lung cancer and COPD.

Recently, several studies have focused on the analysis of epigenetic modifications in the muscles of COPD patients. As such, in patients with mild COPD, miR-1 expression was increased and positively correlated with airway obstruction and quadriceps force.[11] Importantly, the expression of miR-1, miR-206, and miR-27a, levels of lysine-acetylated proteins and histones, and acetylated histone 3 were increased in the quadriceps of COPD patients, especially in those with muscle weakness and wasting, while expression of HDAC3, HDAC4, and sirtuin-1 were reduced.[12] In other experiments, levels of miR-1 levels were lower, while those of HDAC4 were higherin the vastus lateralis of COPD patients with preserved body composition.[13] Furthermore, levels of the transcription factor Yin Yang (YY)1, which modifies histones, inversely correlated with the size of slow- and fast-twitch fibers in the limb muscles of COPD patients with normal body composition.[14] Interestingly, systemic levels of muscle-specific microRNAs were also upregulated in patients with severe COPD and normal body composition.[15] In summary, several epigenetic events that are differentially expressed in the limb muscles of COPD patients with and without muscle mass loss may counterbalance the underlying mechanisms that deteriorate their muscle mass and function.

Further research is still required in order to identify additional mechanisms that may also underlie the etiology of skeletal muscle dysfunction in patients with COPD. We need to identify new cellular and molecular mechanisms that can be specifically targeted using pharmacological strategies and/or exercise modalities to prevent skeletal muscle from undergoing further functional deterioration and wasting.

Conflict of Interest

The author has no conflict of interest relating to this manuscript

Acknowledgments

CIBERES, FIS 14/00713, SEPAR 2013, SEPAR 2016, FUCAP 2011, FUCAP 2012, FUCAP 2014, FUCAP 2016.

References

1. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:809–13.
2. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36:81–8.
3. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62:115–20.
4. Barreiro E, Gea J. Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease. Chron Respir Dis. 2016, pii: 1479972316642366.
5. Barreiro E, Rabinovich R, Marin-Corral J, Barbera JA, Gea J, Roca J. Chronic endurance exercise induces quadriceps nitrosative stress in patients with severe COPD. Thorax. 2009;64:13–9.
6. Fermoselle C, Rabinovich R, Ausin P, Puig-Vilanova E, Coronell C, Sánchez F, et al. Does oxidative stress modulate limb muscle atrophy in severe COPD patients? Eur Respir J. 2012;40:851–62.
7. Puig-Vilanova E, Rodríguez DA, Lloreta J, Ausin P, Pascual-Guardia S, Broquetas J, et al. Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. Free Radic Biol Med. 2015;79:91–108.
8. Rodríguez DA, Kalko S, Puig-Vilanova E, Pérez-Olabarría M, Falciani F, Gea J, et al. Muscle and blood redox status after exercise training in severe COPD patients. Free Radic Biol Med. 2012;52:88–94.
9. Guo Y, Gosker HR, Schols AM, Kapchinsky S, Bourbeau J, Sandri M, et al. Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:1313–20.
10. Barreiro E, Ferrer D, Sánchez F, Minguella J, Marín-Corral J, Martínez-Llorens J, et al. Inflammatory cells and apoptosis in respiratory and limb muscles of patients with COPD. J Appl Physiol. 2011;111:808–17.
11. Puig-Vilanova E, Ausin P, Martínez-Llorens J, Gea J, Barreiro E. Do epigenetic events take place in the *vastus lateralis* of patients with mild chronic obstructive pulmonary disease? PLOS ONE. 2014;9:e102296.
12. Puig-Vilanova E, Martínez-Llorens J, Ausin P, Roca J, Gea J, Barreiro E. Quadriceps muscle weakness and atrophy are associated with a differential epigenetic profile in advanced COPD. Clin Sci (Lond). 2015;128:905–21.
13. Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, et al. Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD. Thorax. 2012;67:26–34.
14. Natanek SA, Riddoch-Contreras J, Marsh GS, Hopkinson NS, Man WD, Moxham J, et al. Yin Yang 1 expression and localisation in quadriceps muscle in COPD. Arch Bronconeumol. 2011;47:296–302.
15. Donaldson A, Natanek SA, Lewis A, Man WD, Hopkinson NS, Polkey MI, et al. Increased skeletal muscle-specific microRNA in the blood of patients with COPD. Thorax. 2013;68:1140–9.